Sign InT2 Biosystems Faces Turbulent Times with Share Reselling and Potential Stock Split
Summary
T2 Biosystems, Inc.'s stock price has experienced a substantial decline and is currently not profitable, but the company's fight against sepsis through its differentiated products could potentially uplift future revenue streams; however, with upcoming uncertainty surrounding a shareholder meeting and potential reverse stock split, it would be prudent to monitor the stock closely and hold off on making any immediate investment decisions until after the meeting on September 12, 2023. (August 24, 2023)
Fundamental Analysis
T2 Biosystems, Inc. (NASDAQ: TTOO) is a healthcare diagnostics company with a market cap of approximately $117.39 million. Recent news has signaled that the company plans to resell approximately 141 million shares which sent the price down by about 15%. The move marked a substantial decline in its stock price, decreasing by 26.35% to $0.35 on August 24, 2023.
The healthcare firm's unstable stock price is also evidenced by its earnings per share (EPS) of -$2.76 and its PE ratio of -0.13, suggesting T2 Biosystems is currently not profitable. However, TTOO stands out due to its fight against sepsis utilizing its “highly differentiated” products — a positive element that could potentially uplift future revenue streams.
The second development expressed in the news is that T2 Biosystems will vote on a reverse stock split in a shareholder meeting on September 12. The reversal could range between 1-for-50 and 1-for-150, which might simultaneously elevate the stock price whilst reducing the number of outstanding shares (currently at 333.58 million shares). This action could potentially increase the earning power per share, providing an artificial price hike to attract investors who shy away from low-priced shares.
This comes alongside other reports of significant volatility in T2 Biosystems' stock with reports of rapid fluctuations and high trading volumes. The company has also been recognized as part of a recent trend in "meme-like buzz," which could explain the heightened trading activity and volatility.
Technical Analysis
On the technical front, the stock’s relative strength index (RSI14) stands at 56, nearing overbought status. It last closed near its 50-day moving average of $0.20136, well below its 200-day moving average of $0.75487. Additionally, the 3-month MACD is 0.132597, suggesting the stock may be losing momentum.
Yet the considerable daily traded volume of 103.1 million shares, although slightly below the average volume of 112.2 million shares, could signal strong investor interest. The stock also operates within a low-high range of $0.054-$6.6.
Stock Prediction
Considering the company’s turbulent state, characterized by high volatility, low profitability, an incoming reverse stock split, and recent news of shareholder reselling, predicting TTOO’s stock price becomes challenging. For the next trading day (August 25, 2023) and the following week, considering market dynamics plus external forces related to the stock split decision, the share price may continue to experience fluctuations.
Given the volatile nature of the stock and T2's current support-resistance levels (Support: $0.35, Resistance: $0.39), it could trade within this range in the coming days. However, the stop-loss point has been set at $0.33, indicative of increased potential for risk if the stock falls below this point.
Evaluation
Given the ongoing uncertainty surrounding the TTOO stock, the financial evaluation would recommend a HOLD rating on T2 Biosystems, Inc. The company's upcoming shareholder meeting and potential reverse stock split add an element of uncertainty that could significantly impact the stock price.
At present, it would be prudent to continue closely monitoring T2's performance, particularly following the shareholder meeting on September 12, 2023. Also, the company’s developments in sepsis products could result in substantial future growth, subject to the scale of acceptance and demand in the healthcare sector.
